Issue 149 • December 2024

Pharma's green shift with dry powder inhalers

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked

Briefing

Sanofi’s $17bn sale of Opella to US investors advances following government deal

Feature

Psoriasis biosimilars and price changes disrupt treatment paradigms

Analyst Comment

For pharma companies, the possibilities of green chemistry are huge

The Big Interview

Will the tide turn for the wave of pharma layoffs?